Although anti-TNF agents have been widely used for the treatment of IBD, new treatment options are being actively explored, mainly due to the loss of response to anti-TNF therapy observed in around 30% of IBD patients [5]. This evidence concerns the gene TNF and inflammatory bowel disease.